After a rocky road to approval and two amendments to the original pact, Akebia Therapeutics and CSL Vifor have terminated their collaboration around the oral chronic kidney disease (CKD ...

THERE is nothing more frustrating than curating the perfect garden only for it to be spoiled by an unsightly fence. However, ...

Akebia Therapeutics, Inc. AKBA announced that the FDA has approved its Vafseo (vadadustat) tablets for the treatment of ...

Akebia Therapeutics on Thursday said it regained full rights to sell the anaemia treatment in the U.S. following a royalty-based termination agreement with CSL Vifor. The biopharmaceutical company ...

The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GSK’s Jesduvroq.

Akebia Therapeutics (NASDAQ:AKBA) announced Thursday that it has regained full rights to sell its newly approved kidney disease therapy Vafseo (vadadustat) in the U.S. after its partner CSL Vifor ...

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced key updates pertaining to the commercial launch of Vafseo ...

(RTTNews) - Akebia Therapeutics (AKBA) issued updates related to the commercial launch of Vafseo or vadadustat Tablets. Vafseo WAC has been set at $1,278 for a 30-day supply at the minimum ...

Akebia brought on its new CFO from Cambridge’s Avrobio, while Frontier Medicines has a new financial leader who was previously an investment banker and violinist. The comings and goings at ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Akebia regains full rights to sell Vafseo® (vadadustat) Tablets in the U.S. following the execution of a royalty-based termination agreement with CSL Vifor to simplify operational execution and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...